Ixazomib

(Ninlaro®)

Ixazomib

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 2.3 mg, 3 mg, 4 mg)
Drug ClassProteasome inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Ninlaro (ixazomib) Prescribing Information.2022Takeda Pharmaceutical Company Limited, Cambridge, MA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma2023Hematology
Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis2023Hematology
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma2023Blood cancer journal
Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis2021Hematology
Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis.2020European Journal of Haematology
Final clinical guidance report: ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.2019CADTH
A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis.2018Clinical Lymphoma, Myeloma & Leukemia
A comparison of the efficacy of immunomodulatory-containing regimens in relapsed/refractory multiple myeloma: a network meta-analysis2018Technology in Cancer Research & Treatment
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma2018Annals of hematology
Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis2018Cancer management and research
Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States2018Journal of managed care & specialty pharmacy
The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma2018BMC medical research methodology